A phase I/II trial of AB928 in combination with AB122 in cancer patients.
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs AB-122 (Primary) ; AB-928 (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Arcus Biosciences
- 20 Nov 2017 New trial record
- 13 Nov 2017 According to an Arcus Biosciences media release, the company is planning to initiate this trial during the first half of 2018.